Pharvaris Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Pharvaris kazanç ve gelirin sırasıyla yıllık 10.1% ve 78.4% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 15.4% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -93.9% olacağı tahmin edilmektedir.

Anahtar bilgiler

10.1%

Kazanç büyüme oranı

15.4%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	23.9%
Gelir büyüme oranı	78.4%
Gelecekteki özkaynak getirisi	-93.9%
Analist kapsamı	Good
Son güncelleme	21 Nov 2024

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:PHVS - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (EUR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	8	-172	-190	-168	6
12/31/2025	N/A	-161	-165	-142	5
12/31/2024	N/A	-138	-133	-116	5
9/30/2024	N/A	-132	-109	-109	N/A
6/30/2024	N/A	-114	-99	-99	N/A
3/31/2024	N/A	-106	-92	-92	N/A
12/31/2023	N/A	-101	-93	-93	N/A
9/30/2023	N/A	-107	-90	-90	N/A
6/30/2023	N/A	-92	-81	-81	N/A
3/31/2023	N/A	-83	-75	-74	N/A
12/31/2022	N/A	-76	-67	-67	N/A
9/30/2022	N/A	-49	-59	-59	N/A
6/30/2022	N/A	-50	-54	-54	N/A
3/31/2022	N/A	-53	-52	-52	N/A
12/31/2021	N/A	-43	-45	-45	N/A
9/30/2021	N/A	-41	-41	-41	N/A
6/30/2021	N/A	-38	-38	-38	N/A
3/31/2021	N/A	-29	-29	-29	N/A
12/31/2020	N/A	-26	-22	-21	N/A
9/30/2020	N/A	-19	-16	-16	N/A
12/31/2019	N/A	-8	-7	-7	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: PHVS önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: PHVS önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: PHVS önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: PHVS gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Yüksek Büyüme Geliri: PHVS gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: PHVS 3 yıl içinde kârsız olması bekleniyor.

Pharvaris Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

New major risk - Revenue and earnings growth

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V. Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings

Pharvaris N.V. Announces Resignation of Morgan Conn as Chief Business Officer, Effective October 4, 2024

Co-Founder notifies of intention to sell stock

Pharvaris Expands Development Program for Deucrictibant

Co-Founder notifies of intention to sell stock

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Pharvaris N.V. Appoints David Nassif as Permanent Chief Legal Officer

Pharvaris N.V., Annual General Meeting, Jun 28, 2024

Pharvaris N.V., Annual General Meeting, Jun 28, 2024

Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses

Pharvaris N.V. Announces Chief Legal Officer Changes, Effective June 1, 2024

Chief Business Officer notifies of intention to sell stock

New minor risk - Share price stability

Chief Early Development Officer notifies of intention to sell stock

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

Independent Vice Chairman notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Pharvaris: Digging Deep For Sufficient Market Size

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V. Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-Demand Treatment of HAE At the GA²LEN UCARE Conference 2023

New major risk - Shareholder dilution

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V. has completed a Follow-on Equity Offering in the amount of $299.98625 million.

Pharvaris N.V. has completed a Follow-on Equity Offering in the amount of $299.98625 million.

Pharvaris Announces Positive Top-Line Phase 2 Data from the Chapter-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Co-Founder notifies of intention to sell stock

Pharvaris Appoints Stefan Abele as Chief Technical Operations Officer

New major risk - Revenue and earnings growth

Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Chief Medical Officer notifies of intention to sell stock

New major risk - Share price stability

Co-Founder notifies of intention to sell stock

Pharvaris N.V. Announces Board Changes

Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE

Pharvaris Announces Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023

Pharvaris N.V., Annual General Meeting, Jun 23, 2023

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

Companies Like Pharvaris (NASDAQ:PHVS) Are In A Position To Invest In Growth

Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks

Less than half of directors are independent

Pharvaris Presents Data Supporting HAE Drug Development Strategy At the 2022 HAEi Global Leadership Workshop

Pharvaris Announces the Promotion of Annick Deschoolmeester to Chief Human Resources Officer

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Pharvaris GAAP EPS of -€0.38

Pharvaris Announces FDA Clinical Hold on PHA121 Clinical Trials in the U.S

Pharvaris slips 19% after FDA clinical hold on hereditary angioedema candidate

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V., Annual General Meeting, Jun 29, 2022

We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

Pharvaris N.V. Appoints Joan Schmidt as Chief Legal Officer

Less than half of directors are independent

High number of new and inexperienced directors

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

Pharvaris reports Q1 results

Independent Non-Executive Director has left the company

Pharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study Evaluating PHVS416 for the On-Demand Treatment of HAE

Pharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE

Pharvaris B.V. has completed an IPO in the amount of $165.41 million.

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin